Two specific inhibitors for emerging cancer therapy target malic enzyme 2 (ME2) are identified and are shown to bind to one of ME2 allosteric sites, resulting in inactive open conformation, inhibiting ME2-mediated cellular respiration and ATP production in the cell. The gene discussed is ME2; the disease is cancer.